InVivoMAb Anti-Influenza B virus NA/Neuraminidase Broad-Neutralizing Antibody (DA03E17)

InVivoMAb Anti-Influenza B virus NA/Neuraminidase Broad-Neutralizing Antibody (DA03E17)

The InVivoMAb Anti-Influenza B virus NA/Neuraminidase Broad-Neutralizing Antibody (DA03E17) is a highly effective and specialized antibody designed to target the neuraminidase (NA) protein of Influenza B virus. This antibody is specifically engineered to provide broad-neutralizing activity against multiple strains of Influenza B virus, making it a valuable tool for researchers and scientists in the field of biotechnology.

Biological Function

The InVivoMAb Anti-Influenza B virus NA/Neuraminidase Broad-Neutralizing Antibody (DA03E17) works by binding to the NA protein of Influenza B virus, preventing it from cleaving sialic acid residues on the surface of host cells. This crucial step in the viral replication process is necessary for the virus to spread and cause infection. By targeting and blocking this key protein, the antibody effectively neutralizes the virus and prevents its further spread.

Main Applications

This powerful antibody has a wide range of applications in the field of biotechnology. It can be used for in vitro assays to study the NA protein and its role in Influenza B virus infection. Additionally, it can be utilized in in vivo studies to evaluate the efficacy of potential antiviral drugs or vaccines against Influenza B virus. The antibody can also be used in diagnostic tests to detect the presence of Influenza B virus in patient samples.

Experimental Use Cases

The InVivoMAb Anti-Influenza B virus NA/Neuraminidase Broad-Neutralizing Antibody (DA03E17) has been extensively studied and proven to be highly effective in various experimental settings. In one study, the antibody was used to successfully inhibit the replication of multiple strains of Influenza B virus in cell culture. In another study, it was shown to provide significant protection against Influenza B virus infection in animal models. These results highlight the potential of this antibody as a valuable tool for Influenza B virus research.

In conclusion, the InVivoMAb Anti-Influenza B virus NA/Neuraminidase Broad-Neutralizing Antibody (DA03E17) is a specialized and powerful tool for studying and combating Influenza B virus. Its broad-neutralizing activity, along with its various applications and proven efficacy in experimental studies, make it an essential component in biotech research. Order now to enhance your research and contribute to the fight against Influenza B virus.